
ACT Brief: APAC Trial Advantages, Learning From Setbacks, and Sunharbo Stroke Prevention Approval
2026-11-11
0:00
1:41
In today’s ACT Brief, we examine why APAC is attractive for global Phase III programs, how clinical research professionals can turn a failed pivotal trial into a redesigned success, and how FDA approved Sunharbo to reduce recurrent stroke risk.
Fler avsnitt från "Applied Clinical Trials"



Missa inte ett avsnitt av “Applied Clinical Trials” och prenumerera på det i GetPodcast-appen.








